Oxaliplatin (OXL)
Oxaliplatin is a platinum-based antineoplastic agent that is used in cancer chemotherapy. The compound features a square planar platinum(II) center. In contrast to cisplatin and carboplatin, oxaliplatin features the bidentate ligand 1,2-diaminocyclohexane in place of the two monodentate ammine ligands. It also features a bidentate oxalate group.
Oxaliplatin is typically administered with fluorouracil and leucovorin in a combination known as FOLFOX for the treatment of colorectal cancer. Oxaliplatin is marketed by Sanofi-Aventis under the trademark Eloxatin or by Medac GmbH under the trademark Oxaliplatin Medac. There are generic equivalents on the market now[4] Oxaliplatin has been compared with other platinum compounds (Cisplatin, Carboplatin) in advanced cancers (gastric, ovarian).

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Oxaliplatin (OXL) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Oxaliplatin (OXL) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Oxaliplatin (OXL) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Oxaliplatin (OXL) CLIA Kit Customized Service Offer
n/a ELISA Kit for Oxaliplatin (OXL) ELISA Kit Customized Service Offer